Note 4 - Novartis Agreement	3 Months Ended
Mar. 31, 2013
Novartis Agreement [Text Block]	4. Novartis Agreement In April 2004, the Company signed a worldwide licensing agreement with Novartis for a value before royalties of up to $18,700,000 to allow Novartis to manufacture calcitonin using its patented peptide production process. The Company has received an aggregate of $13,700,000 from Novartis under this agreement and there are up to $5,000,000 in potential milestone payments remaining. The Company will receive royalties, at rates in the single digits, on net sales of any existing or future Novartis products that contain recombinant salmon calcitonin which in the future are approved for sale by health authorities, and are manufactured by Novartis using its technology. For the three months ended March 31, 2013 and 2012, the Company recognized $223,000 in licensing revenue. Although the Novartis agreement has not been formally terminated, Novartis has informed the Company that due to the failure of its late stage clinical development program, it has no further need to manufacture calcitonin utilizing the Company’s patented peptide production process. The Company expects the agreement to be terminated in 2013, which will result in the recognition of the remaining deferred licensing revenues.

Note 4 - Novartis Agreement

3 Months Ended

Mar. 31, 2013

4. Novartis Agreement

In April 2004, the Company signed a worldwide licensing agreement with Novartis for a value before royalties of up to $18,700,000 to allow Novartis to manufacture calcitonin using its patented peptide production process. The Company has received an aggregate of $13,700,000 from Novartis under this agreement and there are up to $5,000,000 in potential milestone payments remaining. The Company will receive royalties, at rates in the single digits, on net sales of any existing or future Novartis products that contain recombinant salmon calcitonin which in the future are approved for sale by health authorities, and are manufactured by Novartis using its technology. For the three months ended March 31, 2013 and 2012, the Company recognized $223,000 in licensing revenue. Although the Novartis agreement has not been formally terminated, Novartis has informed the Company that due to the failure of its late stage clinical development program, it has no further need to manufacture calcitonin utilizing the Company’s patented peptide production process. The Company expects the agreement to be terminated in 2013, which will result in the recognition of the remaining deferred licensing revenues.